| Literature DB >> 12798327 |
Regina Ortmann1, Jochen Wiesner, Armin Reichenberg, Dajana Henschker, Ewald Beck, Hassan Jomaa, Martin Schlitzer.
Abstract
FR900098 represents an improved derivative of the new antimalarial drug fosmidomycin and acts through inhibition of the 1-deoxy-D-xylulose 5-phosphate (DOXP) reductoisomerase, an essential enzyme of the mevalonate independent pathway of isoprenoid biosynthesis. Prodrugs with increased activity after oral administration were obtained by chemical modification of the phosphonate moiety to yield acyloxyalkyl esters. The most successful compound demonstrated 2-fold increased activity in mice infected with the rodent malaria parasite Plasmodium vinckei.Entities:
Mesh：
Substances：
Year: 2003 PMID： 12798327 DOI： 10.1016/s0960-894x(03)00354-8
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN： 0960-894X Impact factor: 2.823